These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26143912)

  • 21. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
    Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
    Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
    Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
    Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells.
    Wong LH; McGhie JD; Sim M; Anderson MA; Ahn S; Hannan RD; George AJ; Morgan KA; Mann JR; Choo KH
    Genome Res; 2010 Mar; 20(3):351-60. PubMed ID: 20110566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
    Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
    Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
    Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
    Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compromised Telomeric Heterochromatin Promotes ALTernative Lengthening of Telomeres.
    Voon HPJ; Collas P; Wong LH
    Trends Cancer; 2016 Mar; 2(3):114-116. PubMed ID: 28741530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BLM helicase unwinds lagging strand substrates to assemble the ALT telomere damage response.
    Jiang H; Zhang T; Kaur H; Shi T; Krishnan A; Kwon Y; Sung P; Greenberg RA
    Mol Cell; 2024 May; 84(9):1684-1698.e9. PubMed ID: 38593805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
    Mori JO; Keegan J; Flynn RL; Heaphy CM
    J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
    Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
    Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging roles of ATRX in cancer.
    Watson LA; Goldberg H; Bérubé NG
    Epigenomics; 2015; 7(8):1365-78. PubMed ID: 26646632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes.
    Min J; Wright WE; Shay JW
    Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28760773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.
    Lewis PW; Elsaesser SJ; Noh KM; Stadler SC; Allis CD
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14075-80. PubMed ID: 20651253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
    Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
    Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.